

References:

1. <https://www.medscape.com/viewarticle/977398>
2. Lalani HS, Kesselheim AS, Rome BN. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company. *Ann Intern Med.* 2022 Jul;175(7):1053-1055. doi: 10.7326/M22-0756. Epub 2022 Jun 21. Erratum in: *Ann Intern Med.* 2022 Jul 12;; PMID: 35724381. https://www.acpjournals.org/doi/10.7326/M22-0756?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
3. <https://costplusdrugs.com/medications/categories/cancer/>
4. <https://wset.com/news/nation-world/can-mark-cubans-new-prescription-drug-company-really-bring-down-prices-mark-cuban-cost-plus-drug-company-drug-industry-medicare-pharmacy-benefit-managers-medication-prices>
5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557441/>
6. Ruder AD, Smith DL, Madsen MT, Kass FH 3rd. Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic? *J Oncol Pharm Pract.* 2011 Dec;17(4):425-32. doi: 10.1177/1078155210389216. Epub 2011 Jan 19. PMID: 21248174. <https://pubmed.ncbi.nlm.nih.gov/21248174/>